|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:VBP1-BRCC3 (FusionGDB2 ID:97959) |
Fusion Gene Summary for VBP1-BRCC3 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: VBP1-BRCC3 | Fusion gene ID: 97959 | Hgene | Tgene | Gene symbol | VBP1 | BRCC3 | Gene ID | 7411 | 79184 |
| Gene name | VHL binding protein 1 | BRCA1/BRCA2-containing complex subunit 3 | |
| Synonyms | HIBBJ46|PFD3|PFDN3|VBP-1 | BRCC36|C6.1A|CXorf53 | |
| Cytomap | Xq28 | Xq28 | |
| Type of gene | protein-coding | protein-coding | |
| Description | prefoldin subunit 3von Hippel-Lindau binding protein 1 | lys-63-specific deubiquitinase BRCC36BRCA1-A complex subunit BRCC36BRCA1/BRCA2-containing complex subunit 36BRISC complex subunit BRCC36 | |
| Modification date | 20200313 | 20200313 | |
| UniProtAcc | . | P46736 | |
| Ensembl transtripts involved in fusion gene | ENST00000286428, ENST00000459836, ENST00000535916, | ENST00000399042, ENST00000330045, ENST00000340647, ENST00000369459, ENST00000369462, | |
| Fusion gene scores | * DoF score | 4 X 2 X 4=32 | 3 X 3 X 2=18 |
| # samples | 4 | 3 | |
| ** MAII score | log2(4/32*10)=0.321928094887362 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | log2(3/18*10)=0.736965594166206 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | |
| Context | PubMed: VBP1 [Title/Abstract] AND BRCC3 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | VBP1(154444852)-BRCC3(154300602), # samples:2 | ||
| Anticipated loss of major functional domain due to fusion event. | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Tgene | BRCC3 | GO:0010165 | response to X-ray | 14636569 |
| Tgene | BRCC3 | GO:0070536 | protein K63-linked deubiquitination | 17525341|19214193 |
| Tgene | BRCC3 | GO:0070537 | histone H2A K63-linked deubiquitination | 19202061 |
| Fusion gene breakpoints across VBP1 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene breakpoints across BRCC3 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | BRCA | TCGA-S3-A6ZG-01A | VBP1 | chrX | 154444852 | - | BRCC3 | chrX | 154300602 | + |
| ChimerDB4 | GBM | TCGA-06-A6S1-01A | VBP1 | chrX | 154444852 | + | BRCC3 | chrX | 154300602 | + |
Top |
Fusion Gene ORF analysis for VBP1-BRCC3 |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| 5CDS-intron | ENST00000286428 | ENST00000399042 | VBP1 | chrX | 154444852 | + | BRCC3 | chrX | 154300602 | + |
| In-frame | ENST00000286428 | ENST00000330045 | VBP1 | chrX | 154444852 | + | BRCC3 | chrX | 154300602 | + |
| In-frame | ENST00000286428 | ENST00000340647 | VBP1 | chrX | 154444852 | + | BRCC3 | chrX | 154300602 | + |
| In-frame | ENST00000286428 | ENST00000369459 | VBP1 | chrX | 154444852 | + | BRCC3 | chrX | 154300602 | + |
| In-frame | ENST00000286428 | ENST00000369462 | VBP1 | chrX | 154444852 | + | BRCC3 | chrX | 154300602 | + |
| intron-3CDS | ENST00000459836 | ENST00000330045 | VBP1 | chrX | 154444852 | + | BRCC3 | chrX | 154300602 | + |
| intron-3CDS | ENST00000459836 | ENST00000340647 | VBP1 | chrX | 154444852 | + | BRCC3 | chrX | 154300602 | + |
| intron-3CDS | ENST00000459836 | ENST00000369459 | VBP1 | chrX | 154444852 | + | BRCC3 | chrX | 154300602 | + |
| intron-3CDS | ENST00000459836 | ENST00000369462 | VBP1 | chrX | 154444852 | + | BRCC3 | chrX | 154300602 | + |
| intron-3CDS | ENST00000535916 | ENST00000330045 | VBP1 | chrX | 154444852 | + | BRCC3 | chrX | 154300602 | + |
| intron-3CDS | ENST00000535916 | ENST00000340647 | VBP1 | chrX | 154444852 | + | BRCC3 | chrX | 154300602 | + |
| intron-3CDS | ENST00000535916 | ENST00000369459 | VBP1 | chrX | 154444852 | + | BRCC3 | chrX | 154300602 | + |
| intron-3CDS | ENST00000535916 | ENST00000369462 | VBP1 | chrX | 154444852 | + | BRCC3 | chrX | 154300602 | + |
| intron-intron | ENST00000459836 | ENST00000399042 | VBP1 | chrX | 154444852 | + | BRCC3 | chrX | 154300602 | + |
| intron-intron | ENST00000535916 | ENST00000399042 | VBP1 | chrX | 154444852 | + | BRCC3 | chrX | 154300602 | + |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000286428 | VBP1 | chrX | 154444852 | + | ENST00000340647 | BRCC3 | chrX | 154300602 | + | 1080 | 210 | 9 | 965 | 318 |
| ENST00000286428 | VBP1 | chrX | 154444852 | + | ENST00000330045 | BRCC3 | chrX | 154300602 | + | 2486 | 210 | 9 | 962 | 317 |
| ENST00000286428 | VBP1 | chrX | 154444852 | + | ENST00000369459 | BRCC3 | chrX | 154300602 | + | 2699 | 210 | 9 | 830 | 273 |
| ENST00000286428 | VBP1 | chrX | 154444852 | + | ENST00000369462 | BRCC3 | chrX | 154300602 | + | 2908 | 210 | 9 | 1037 | 342 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
| ENST00000286428 | ENST00000340647 | VBP1 | chrX | 154444852 | + | BRCC3 | chrX | 154300602 | + | 0.004312927 | 0.99568707 |
| ENST00000286428 | ENST00000330045 | VBP1 | chrX | 154444852 | + | BRCC3 | chrX | 154300602 | + | 0.001029553 | 0.9989705 |
| ENST00000286428 | ENST00000369459 | VBP1 | chrX | 154444852 | + | BRCC3 | chrX | 154300602 | + | 0.00172166 | 0.9982784 |
| ENST00000286428 | ENST00000369462 | VBP1 | chrX | 154444852 | + | BRCC3 | chrX | 154300602 | + | 0.000852165 | 0.9991478 |
Top |
Fusion Genomic Features for VBP1-BRCC3 |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| VBP1 | chrX | 154444852 | + | BRCC3 | chrX | 154300601 | + | 0.016380217 | 0.9836198 |
| VBP1 | chrX | 154444852 | + | BRCC3 | chrX | 154300601 | + | 0.016380217 | 0.9836198 |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
 |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
 |
Top |
Fusion Protein Features for VBP1-BRCC3 |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chrX:154444852/chrX:154300602) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| . | BRCC3 |
| FUNCTION: Transcriptional activator which is required for calcium-dependent dendritic growth and branching in cortical neurons. Recruits CREB-binding protein (CREBBP) to nuclear bodies. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating a calcium-dependent release of a repressor complex and a recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves a release of HDAC1 and recruitment of CREBBP (By similarity). {ECO:0000250}. | FUNCTION: Metalloprotease that specifically cleaves 'Lys-63'-linked polyubiquitin chains (PubMed:19214193, PubMed:20656690, PubMed:24075985, PubMed:26344097). Does not have activity toward 'Lys-48'-linked polyubiquitin chains. Component of the BRCA1-A complex, a complex that specifically recognizes 'Lys-63'-linked ubiquitinated histones H2A and H2AX at DNA lesions sites, leading to target the BRCA1-BARD1 heterodimer to sites of DNA damage at double-strand breaks (DSBs). In the BRCA1-A complex, it specifically removes 'Lys-63'-linked ubiquitin on histones H2A and H2AX, antagonizing the RNF8-dependent ubiquitination at double-strand breaks (DSBs) (PubMed:20656690). Catalytic subunit of the BRISC complex, a multiprotein complex that specifically cleaves 'Lys-63'-linked ubiquitin in various substrates (PubMed:20656690, PubMed:24075985, PubMed:26344097, PubMed:26195665). Mediates the specific 'Lys-63'-specific deubiquitination associated with the COP9 signalosome complex (CSN), via the interaction of the BRISC complex with the CSN complex (PubMed:19214193). The BRISC complex is required for normal mitotic spindle assembly and microtubule attachment to kinetochores via its role in deubiquitinating NUMA1 (PubMed:26195665). Plays a role in interferon signaling via its role in the deubiquitination of the interferon receptor IFNAR1; deubiquitination increases IFNAR1 activity by enhancing its stability and cell surface expression (PubMed:24075985, PubMed:26344097). Down-regulates the response to bacterial lipopolysaccharide (LPS) via its role in IFNAR1 deubiquitination (PubMed:24075985). {ECO:0000269|PubMed:14636569, ECO:0000269|PubMed:16707425, ECO:0000269|PubMed:17525341, ECO:0000269|PubMed:19202061, ECO:0000269|PubMed:19214193, ECO:0000269|PubMed:19261746, ECO:0000269|PubMed:19261748, ECO:0000269|PubMed:19261749, ECO:0000269|PubMed:20656690, ECO:0000269|PubMed:24075985, ECO:0000269|PubMed:26195665, ECO:0000269|PubMed:26344097}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Tgene | BRCC3 | chrX:154444852 | chrX:154300602 | ENST00000330045 | 0 | 11 | 122_135 | 41 | 720.3333333333334 | Motif | JAMM motif | |
| Tgene | BRCC3 | chrX:154444852 | chrX:154300602 | ENST00000340647 | 0 | 11 | 122_135 | 41 | 248.0 | Motif | JAMM motif | |
| Tgene | BRCC3 | chrX:154444852 | chrX:154300602 | ENST00000369459 | 0 | 10 | 122_135 | 41 | 814.0 | Motif | JAMM motif | |
| Tgene | BRCC3 | chrX:154444852 | chrX:154300602 | ENST00000369462 | 0 | 12 | 122_135 | 41 | 885.0 | Motif | JAMM motif |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Tgene | BRCC3 | chrX:154444852 | chrX:154300602 | ENST00000330045 | 0 | 11 | 12_179 | 41 | 720.3333333333334 | Domain | MPN | |
| Tgene | BRCC3 | chrX:154444852 | chrX:154300602 | ENST00000340647 | 0 | 11 | 12_179 | 41 | 248.0 | Domain | MPN | |
| Tgene | BRCC3 | chrX:154444852 | chrX:154300602 | ENST00000369459 | 0 | 10 | 12_179 | 41 | 814.0 | Domain | MPN | |
| Tgene | BRCC3 | chrX:154444852 | chrX:154300602 | ENST00000369462 | 0 | 12 | 12_179 | 41 | 885.0 | Domain | MPN |
Top |
Fusion Gene Sequence for VBP1-BRCC3 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >97959_97959_1_VBP1-BRCC3_VBP1_chrX_154444852_ENST00000286428_BRCC3_chrX_154300602_ENST00000330045_length(transcript)=2486nt_BP=210nt TGCGCACCAATGAATGTGCATGGAGATGGAGAGGCGGGCCTGCAAGTGCGAACAAGCCAATCACGGAATCCCGGCGGCCGGCGGCCCGGG AGGCAGTCGCGCGCTCGCATCCCCAAGATGGCGGCCGTTAAGGACAGTTGTGGCAAAGGAGAAATGGCCACAGGGAATGGGCGGCGGCTC CACCTGGGGATTCCTGAGGCCGTGTTTGTGTTGAACGATGATACAAGGAGTGACTCCAAATTTGCATATACTGGAACTGAAATGCGCACA GTTGCTGAAAAGGTTGATGCCGTCAGAATTGTTCACATTCATTCTGTCATCATCTTACGACGTTCTGATAAGAGGAAGGACCGAGTAGAA ATTTCTCCAGAGCAGCTGTCTGCAGCTTCAACAGAGGCAGAGAGGTTGGCTGAACTGACAGGCCGCCCCATGAGAGTTGTGGGCTGGTAT CATTCCCATCCTCATATAACTGTTTGGCCTTCACATGTTGATGTTCGCACACAAGCCATGTACCAGATGATGGATCAAGGCTTTGTAGGA CTTATTTTTTCCTGTTTCATAGAAGATAAGAACACAAAGACTGGCCGGGTACTCTACACTTGCTTCCAATCCATACAGGCCCAAAAGAGT TCAGAGTATGAGAGAATCGAAATCCCAATCCATATTGTACCTCATGTCACTATCGGGAAAGTGTGCCTTGAATCAGCAGTAGAGCTGCCC AAGATCCTGTGCCAGGAGGAGCAGGATGCGTATAGGAGGATCCACAGCCTTACACATCTGGACTCAGTAACCAAGATCCATAATGGCTCA GTGTTTACCAAGAATCTGTGCAGTCAGATGTCGGCAGTCAGCGGGCCTCTCCTACAGTGGTTGGAGGACAGACTGGAGCAAAACCAACAG CATTTGCAGGAATTACAACAAGAAAAGGAAGAGCTTATGCAAGAACTTTCTTCTCTAGAATAAATCAGGAGACAAAATGGGGAAAGATGA AAATATCCAGTGTAAAGTTACTTAAGCTAAATCAATTTCAAAGAAGAAAAACTTGGAGGACTCATTTTACCTGACTTCAAGACTTACTAT AAAGCTATAGTAATCAAGATAGATGGTATTGGCAGAGGAACAGACACATACGTCAATGGAACAGATGAGAGAACCCAGAAATAAACCCAT ATAAATATGCTCAGCTGATTTTGAAAAAGTGAAAAAGCAATTCAATGGAGGAAGAATAGCCTTTCTGACAAATTATGCTAGAGCAATTAG ACACCCATGGCGAGGAGAAAAAAGAACCTCTACTTAAACCTCACATCTTATATAAAATTTAACTCAAAATGTATAACGGACTTAAATGTG ATACATAAAACTAGATAACTTTGAAAAAAGCCACAGGAGAAAAATCTTCAGGATCTTGGGCTAGGTGACAAGTTCTTGGACTTTGCCCCG AAAGCACATCCATAAAAGACAAAATCTGATATATTGGACTTCTTCAAAATTTAAAAACTTGTGATTTAAGAAGAGGAAAAGATAAGCTAC AGATTGAGATGAATTTGCAAACCATATATCTGATCAATTTGGAATATATAAAGTGTACTAAAAACTCAACTGAAGTCAGGCATGGTAGCT CATGCTTGTAATCTCACCACTTTGGGAGGCCAAGATGGGAGGAGTGCTTGAGGTTAGGCGTTCCAGACCAGCCTGGGCAACATAGTGAGA CTCTTGTCTCTACAAAAAGTTTTTTTAAAAAATTAACTGGGCACCATGACACACACCAGTAGTCCCAGCTACTAGGGAGGCAGGAGGATC ACTTGAGCCCAGGAGTTTGAGGCTGCGGTGAGCTGTGATCACACCACCACACTCCAACCTGTGTAACAGAGTGAGGCCTCATCTCAAAAA AAAAAAAAGGCCACAAAACTCAACAATAAAAACAAACAGTCCAATTAGAAAATGGGCAAAAGACATGAATAGATGTTTCACTGAAGAGGA TCTATAGATGGCAAGTAAGCATATGAAAAGCTGTTAAACTCCATAAGTCATCAGGGAATGCAAATTGAAACCACAGCGAGGCTATGACTT ACTTATCTCAATGGCTAAAGAAAAAATAGTGAAAATACCAAATACTGATGAGGATACAAACTGGATATTTTATACATTGCTGACAGGAAT GTAAAATGGTACAGCCACTCTGGGAAAGAGTTTATGAATTTCTTATCAAGTTAAACATAATTTTTTAATCAAGTTAAACATAAGACCCAG CAGTTGTGCTCCTGGACATTCATTCCAGAGAAATGAAAACCTATATTGTACTTGTACTCAAATATTCATAGGAGCTTTATTTGTAATAGC CCCAAACTGGAAACAACCCAGATGTCCTACAACAGGTACATGGTTAAACAAACCATCCATAACTTGGAATACTGCTCTGGAATGAAAAGG >97959_97959_1_VBP1-BRCC3_VBP1_chrX_154444852_ENST00000286428_BRCC3_chrX_154300602_ENST00000330045_length(amino acids)=317AA_BP= MNVHGDGEAGLQVRTSQSRNPGGRRPGRQSRARIPKMAAVKDSCGKGEMATGNGRRLHLGIPEAVFVLNDDTRSDSKFAYTGTEMRTVAE KVDAVRIVHIHSVIILRRSDKRKDRVEISPEQLSAASTEAERLAELTGRPMRVVGWYHSHPHITVWPSHVDVRTQAMYQMMDQGFVGLIF SCFIEDKNTKTGRVLYTCFQSIQAQKSSEYERIEIPIHIVPHVTIGKVCLESAVELPKILCQEEQDAYRRIHSLTHLDSVTKIHNGSVFT -------------------------------------------------------------- >97959_97959_2_VBP1-BRCC3_VBP1_chrX_154444852_ENST00000286428_BRCC3_chrX_154300602_ENST00000340647_length(transcript)=1080nt_BP=210nt TGCGCACCAATGAATGTGCATGGAGATGGAGAGGCGGGCCTGCAAGTGCGAACAAGCCAATCACGGAATCCCGGCGGCCGGCGGCCCGGG AGGCAGTCGCGCGCTCGCATCCCCAAGATGGCGGCCGTTAAGGACAGTTGTGGCAAAGGAGAAATGGCCACAGGGAATGGGCGGCGGCTC CACCTGGGGATTCCTGAGGCCGTGTTTGTGTTGAACGATGATACAAGTAGGAGTGACTCCAAATTTGCATATACTGGAACTGAAATGCGC ACAGTTGCTGAAAAGGTTGATGCCGTCAGAATTGTTCACATTCATTCTGTCATCATCTTACGACGTTCTGATAAGAGGAAGGACCGAGTA GAAATTTCTCCAGAGCAGCTGTCTGCAGCTTCAACAGAGGCAGAGAGGTTGGCTGAACTGACAGGCCGCCCCATGAGAGTTGTGGGCTGG TATCATTCCCATCCTCATATAACTGTTTGGCCTTCACATGTTGATGTTCGCACACAAGCCATGTACCAGATGATGGATCAAGGCTTTGTA GGACTTATTTTTTCCTGTTTCATAGAAGATAAGAACACAAAGACTGGCCGGGTACTCTACACTTGCTTCCAATCCATACAGGCCCAAAAG AGTTCAGAGTATGAGAGAATCGAAATCCCAATCCATATTGTACCTCATGTCACTATCGGGAAAGTGTGCCTTGAATCAGCAGTAGAGCTG CCCAAGATCCTGTGCCAGGAGGAGCAGGATGCGTATAGGAGGATCCACAGCCTTACACATCTGGACTCAGTAACCAAGATCCATAATGGC TCAGTGTTTACCAAGAATCTGTGCAGTCAGATGTCGGCAGTCAGCGGGCCTCTCCTACAGTGGTTGGAGGACAGACTGGAGCAAAACCAA CAGCATTTGCAGGAATTACAACAAGAAAAGGAAGAGCTTATGCAAGAACTTTCTTCTCTAGAATAAATCAGGAGACAAAATGGGGAAAGA TGAAAATATCCAGTGTAAAGTTACTTAAGCTAAATCAATTTCAAAGAAGAAAAACTTGGAGGACTCATTTTACCTGACTTCAAGACTTAC >97959_97959_2_VBP1-BRCC3_VBP1_chrX_154444852_ENST00000286428_BRCC3_chrX_154300602_ENST00000340647_length(amino acids)=318AA_BP= MNVHGDGEAGLQVRTSQSRNPGGRRPGRQSRARIPKMAAVKDSCGKGEMATGNGRRLHLGIPEAVFVLNDDTSRSDSKFAYTGTEMRTVA EKVDAVRIVHIHSVIILRRSDKRKDRVEISPEQLSAASTEAERLAELTGRPMRVVGWYHSHPHITVWPSHVDVRTQAMYQMMDQGFVGLI FSCFIEDKNTKTGRVLYTCFQSIQAQKSSEYERIEIPIHIVPHVTIGKVCLESAVELPKILCQEEQDAYRRIHSLTHLDSVTKIHNGSVF -------------------------------------------------------------- >97959_97959_3_VBP1-BRCC3_VBP1_chrX_154444852_ENST00000286428_BRCC3_chrX_154300602_ENST00000369459_length(transcript)=2699nt_BP=210nt TGCGCACCAATGAATGTGCATGGAGATGGAGAGGCGGGCCTGCAAGTGCGAACAAGCCAATCACGGAATCCCGGCGGCCGGCGGCCCGGG AGGCAGTCGCGCGCTCGCATCCCCAAGATGGCGGCCGTTAAGGACAGTTGTGGCAAAGGAGAAATGGCCACAGGGAATGGGCGGCGGCTC CACCTGGGGATTCCTGAGGCCGTGTTTGTGTTGAACGATGATACAAGGAGTGACTCCAAATTTGCATATACTGGAACTGAAATGCGCACA GTTGCTGAAAAGGTTGATGCCGTCAGAATTGTTCACATTCATTCTGTCATCATCTTACGACGTTCTGATAAGAGGAAGGACCGAGTAGAA ATTTCTCCAGAGCAGCTGTCTGCAGCTTCAACAGAGGCAGAGAGGTTGGCTGAACTGACAGGCCGCCCCATGAGAGTTGTGGGCTGGTAT CATTCCCATCCTCATATAACTGTTTGGCCTTCACATGTTGATGTTCGCACACAAGCCATGTACCAGATGATGGATCAAGGCTTTGTAGGA CTTATTTTTTCCTGTTTCATAGAAGATAAGAACACAAAGACTGGCCGGGTACTCTACACTTGCTTCCAATCCATACAGGCCCAAAAGAGT TCAGACCTTACACATCTGGACTCAGTAACCAAGATCCATAATGGCTCAGTGTTTACCAAGAATCTGTGCAGTCAGATGTCGGCAGTCAGC GGGCCTCTCCTACAGTGGTTGGAGGACAGACTGGAGCAAAACCAACAGCATTTGCAGGAATTACAACAAGAAAAGGAAGAGCTTATGCAA GAACTTTCTTCTCTAGAATAAATCAGGAGACAAAATGGGGAAAGATGAAAATATCCAGTGTAAAGTTACTTAAGCTAAATCAATTTCAAA GAAGAAAAACTTGGAGGACTCATTTTACCTGACTTCAAGACTTACTATAAAGCTATAGTAATCAAGATAGATGGTATTGGCAGAGGAACA GACACATACGTCAATGGAACAGATGAGAGAACCCAGAAATAAACCCATATAAATATGCTCAGCTGATTTTGAAAAAGTGAAAAAGCAATT CAATGGAGGAAGAATAGCCTTTCTGACAAATTATGCTAGAGCAATTAGACACCCATGGCGAGGAGAAAAAAGAACCTCTACTTAAACCTC ACATCTTATATAAAATTTAACTCAAAATGTATAACGGACTTAAATGTGATACATAAAACTAGATAACTTTGAAAAAAGCCACAGGAGAAA AATCTTCAGGATCTTGGGCTAGGTGACAAGTTCTTGGACTTTGCCCCGAAAGCACATCCATAAAAGACAAAATCTGATATATTGGACTTC TTCAAAATTTAAAAACTTGTGATTTAAGAAGAGGAAAAGATAAGCTACAGATTGAGATGAATTTGCAAACCATATATCTGATCAATTTGG AATATATAAAGTGTACTAAAAACTCAACTGAAGTCAGGCATGGTAGCTCATGCTTGTAATCTCACCACTTTGGGAGGCCAAGATGGGAGG AGTGCTTGAGGTTAGGCGTTCCAGACCAGCCTGGGCAACATAGTGAGACTCTTGTCTCTACAAAAAGTTTTTTTAAAAAATTAACTGGGC ACCATGACACACACCAGTAGTCCCAGCTACTAGGGAGGCAGGAGGATCACTTGAGCCCAGGAGTTTGAGGCTGCGGTGAGCTGTGATCAC ACCACCACACTCCAACCTGTGTAACAGAGTGAGGCCTCATCTCAAAAAAAAAAAAAGGCCACAAAACTCAACAATAAAAACAAACAGTCC AATTAGAAAATGGGCAAAAGACATGAATAGATGTTTCACTGAAGAGGATCTATAGATGGCAAGTAAGCATATGAAAAGCTGTTAAACTCC ATAAGTCATCAGGGAATGCAAATTGAAACCACAGCGAGGCTATGACTTACTTATCTCAATGGCTAAAGAAAAAATAGTGAAAATACCAAA TACTGATGAGGATACAAACTGGATATTTTATACATTGCTGACAGGAATGTAAAATGGTACAGCCACTCTGGGAAAGAGTTTATGAATTTC TTATCAAGTTAAACATAATTTTTTAATCAAGTTAAACATAAGACCCAGCAGTTGTGCTCCTGGACATTCATTCCAGAGAAATGAAAACCT ATATTGTACTTGTACTCAAATATTCATAGGAGCTTTATTTGTAATAGCCCCAAACTGGAAACAACCCAGATGTCCTACAACAGGTACATG GTTAAACAAACCATCCATAACTTGGAATACTGCTCTGGAATGAAAAGGAACTAACTGTTGATACAAGAACTTGGTTGTACCTCAGGGGTA TTATGGTGAACAAAAAAAAAACCAGTCTCAAATGGTCACATACTGTATGATCGCATTTATATAACATTCTTGAGGTGACAAAATTATTGA AATGAAGAACAGATTAATGGTTGCCAGGGATAGGGACTGGAGGGGGTGTGGGGTATGTATGACTATAAAGGGATGACGCAAGGAGTTCCT TTGTGCTGATGGAACAGTTCTATATGATTATGATGATTACGATGTTGATTATAACATTTGATTATGAGGTTAAGCACATGAGTCTTTACC >97959_97959_3_VBP1-BRCC3_VBP1_chrX_154444852_ENST00000286428_BRCC3_chrX_154300602_ENST00000369459_length(amino acids)=273AA_BP= MNVHGDGEAGLQVRTSQSRNPGGRRPGRQSRARIPKMAAVKDSCGKGEMATGNGRRLHLGIPEAVFVLNDDTRSDSKFAYTGTEMRTVAE KVDAVRIVHIHSVIILRRSDKRKDRVEISPEQLSAASTEAERLAELTGRPMRVVGWYHSHPHITVWPSHVDVRTQAMYQMMDQGFVGLIF SCFIEDKNTKTGRVLYTCFQSIQAQKSSDLTHLDSVTKIHNGSVFTKNLCSQMSAVSGPLLQWLEDRLEQNQQHLQELQQEKEELMQELS -------------------------------------------------------------- >97959_97959_4_VBP1-BRCC3_VBP1_chrX_154444852_ENST00000286428_BRCC3_chrX_154300602_ENST00000369462_length(transcript)=2908nt_BP=210nt TGCGCACCAATGAATGTGCATGGAGATGGAGAGGCGGGCCTGCAAGTGCGAACAAGCCAATCACGGAATCCCGGCGGCCGGCGGCCCGGG AGGCAGTCGCGCGCTCGCATCCCCAAGATGGCGGCCGTTAAGGACAGTTGTGGCAAAGGAGAAATGGCCACAGGGAATGGGCGGCGGCTC CACCTGGGGATTCCTGAGGCCGTGTTTGTGTTGAACGATGATACAAGGAGTGACTCCAAATTTGCATATACTGGAACTGAAATGCGCACA GTTGCTGAAAAGGTTGATGCCGTCAGAATTGTTCACATTCATTCTGTCATCATCTTACGACGTTCTGATAAGAGGAAGGACCGAGTAGAA ATTTCTCCAGAGCAGCTGTCTGCAGCTTCAACAGAGGCAGAGAGGTTGGCTGAACTGACAGGCCGCCCCATGAGAGTTGTGGGCTGGTAT CATTCCCATCCTCATATAACTGTTTGGCCTTCACATGTTGATGTTCGCACACAAGCCATGTACCAGATGATGGATCAAGGCTTTGTAGGA CTTATTTTTTCCTGTTTCATAGAAGATAAGAACACAAAGACTGGCCGGGTACTCTACACTTGCTTCCAATCCATACAGGCCCAAAAGAGT TCAGAGTCCCTTCATGGTCCACGAGACTTCTGGAGCTCCAGCCAGCACATCTCCATTGAGGGCCAGAAGGAAGAGGAAAGGTATGAGAGA ATCGAAATCCCAATCCATATTGTACCTCATGTCACTATCGGGAAAGTGTGCCTTGAATCAGCAGTAGAGCTGCCCAAGATCCTGTGCCAG GAGGAGCAGGATGCGTATAGGAGGATCCACAGCCTTACACATCTGGACTCAGTAACCAAGATCCATAATGGCTCAGTGTTTACCAAGAAT CTGTGCAGTCAGATGTCGGCAGTCAGCGGGCCTCTCCTACAGTGGTTGGAGGACAGACTGGAGCAAAACCAACAGCATTTGCAGGAATTA CAACAAGAAAAGGAAGAGCTTATGCAAGAACTTTCTTCTCTAGAATAAATCAGGAGACAAAATGGGGAAAGATGAAAATATCCAGTGTAA AGTTACTTAAGCTAAATCAATTTCAAAGAAGAAAAACTTGGAGGACTCATTTTACCTGACTTCAAGACTTACTATAAAGCTATAGTAATC AAGATAGATGGTATTGGCAGAGGAACAGACACATACGTCAATGGAACAGATGAGAGAACCCAGAAATAAACCCATATAAATATGCTCAGC TGATTTTGAAAAAGTGAAAAAGCAATTCAATGGAGGAAGAATAGCCTTTCTGACAAATTATGCTAGAGCAATTAGACACCCATGGCGAGG AGAAAAAAGAACCTCTACTTAAACCTCACATCTTATATAAAATTTAACTCAAAATGTATAACGGACTTAAATGTGATACATAAAACTAGA TAACTTTGAAAAAAGCCACAGGAGAAAAATCTTCAGGATCTTGGGCTAGGTGACAAGTTCTTGGACTTTGCCCCGAAAGCACATCCATAA AAGACAAAATCTGATATATTGGACTTCTTCAAAATTTAAAAACTTGTGATTTAAGAAGAGGAAAAGATAAGCTACAGATTGAGATGAATT TGCAAACCATATATCTGATCAATTTGGAATATATAAAGTGTACTAAAAACTCAACTGAAGTCAGGCATGGTAGCTCATGCTTGTAATCTC ACCACTTTGGGAGGCCAAGATGGGAGGAGTGCTTGAGGTTAGGCGTTCCAGACCAGCCTGGGCAACATAGTGAGACTCTTGTCTCTACAA AAAGTTTTTTTAAAAAATTAACTGGGCACCATGACACACACCAGTAGTCCCAGCTACTAGGGAGGCAGGAGGATCACTTGAGCCCAGGAG TTTGAGGCTGCGGTGAGCTGTGATCACACCACCACACTCCAACCTGTGTAACAGAGTGAGGCCTCATCTCAAAAAAAAAAAAAGGCCACA AAACTCAACAATAAAAACAAACAGTCCAATTAGAAAATGGGCAAAAGACATGAATAGATGTTTCACTGAAGAGGATCTATAGATGGCAAG TAAGCATATGAAAAGCTGTTAAACTCCATAAGTCATCAGGGAATGCAAATTGAAACCACAGCGAGGCTATGACTTACTTATCTCAATGGC TAAAGAAAAAATAGTGAAAATACCAAATACTGATGAGGATACAAACTGGATATTTTATACATTGCTGACAGGAATGTAAAATGGTACAGC CACTCTGGGAAAGAGTTTATGAATTTCTTATCAAGTTAAACATAATTTTTTAATCAAGTTAAACATAAGACCCAGCAGTTGTGCTCCTGG ACATTCATTCCAGAGAAATGAAAACCTATATTGTACTTGTACTCAAATATTCATAGGAGCTTTATTTGTAATAGCCCCAAACTGGAAACA ACCCAGATGTCCTACAACAGGTACATGGTTAAACAAACCATCCATAACTTGGAATACTGCTCTGGAATGAAAAGGAACTAACTGTTGATA CAAGAACTTGGTTGTACCTCAGGGGTATTATGGTGAACAAAAAAAAAACCAGTCTCAAATGGTCACATACTGTATGATCGCATTTATATA ACATTCTTGAGGTGACAAAATTATTGAAATGAAGAACAGATTAATGGTTGCCAGGGATAGGGACTGGAGGGGGTGTGGGGTATGTATGAC TATAAAGGGATGACGCAAGGAGTTCCTTTGTGCTGATGGAACAGTTCTATATGATTATGATGATTACGATGTTGATTATAACATTTGATT ATGAGGTTAAGCACATGAGTCTTTACCTGTGCTGAAGTTGTATGGACCTACATACACACAAATGAATGCATGTAAAATCTGGTGATACTG >97959_97959_4_VBP1-BRCC3_VBP1_chrX_154444852_ENST00000286428_BRCC3_chrX_154300602_ENST00000369462_length(amino acids)=342AA_BP= MNVHGDGEAGLQVRTSQSRNPGGRRPGRQSRARIPKMAAVKDSCGKGEMATGNGRRLHLGIPEAVFVLNDDTRSDSKFAYTGTEMRTVAE KVDAVRIVHIHSVIILRRSDKRKDRVEISPEQLSAASTEAERLAELTGRPMRVVGWYHSHPHITVWPSHVDVRTQAMYQMMDQGFVGLIF SCFIEDKNTKTGRVLYTCFQSIQAQKSSESLHGPRDFWSSSQHISIEGQKEEERYERIEIPIHIVPHVTIGKVCLESAVELPKILCQEEQ -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for VBP1-BRCC3 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for VBP1-BRCC3 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for VBP1-BRCC3 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies